📬 Breast Cancer Intelligence Digest — Week 2026-W39

FDA approved imlunestrant plus abemaciclib for ESR1-mutated ER+/HER2- advanced breast cancer, the ABC8 international consensus guidelines landed, a premenopausal HR+/HER2- adjuvant review drew wide clinician attention, and the EGFR-HER3 bispecific ADC iza-bren phase 1b breast data circulated.

⚡ TL;DR

📄 Publications

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. — Premenopausal HR+/HER2- early breast cancer is a clinically distinct population with more aggressive tumor biology and complex treatment decision-making

🐦 Twitter / 🦋 Bluesky

An Annals of Oncology review on premenopausal HR+/HER2- adjuvant therapy becomes the week's most-shared breast paper, with clinicians pointing to its risk-category endocrine figure — The review states that premenopausal HR+/HER2-negative early breast cancer is a clinically distinct population with more aggressive tumor biology and complex treatment decision-making
ABC8 international consensus guidelines for advanced breast cancer: a new endocrine sensitivity/resistance definition, updated subtype algorithms, and first-ever guidance on exercise and artificial intelligence — ABC8 includes an updated definition of endocrine sensitivity/resistance developed with the AURORA Molecular Screening Initiative
FDA approves imlunestrant plus abemaciclib for ESR1-mutated ER+/HER2- advanced breast cancer — the first oral SERD combination in this setting, with immature overall survival — The combination was approved on EMBER-3, where median PFS was 11.1 vs 5.5 months in the ESR1-mutant population
Update: iza-bren's EGFR-HER3 bispecific ADC breast data draw a second week of scrutiny, now focused on therapeutic index and cross-resistance after prior TOP1 inhibitor ADCs — Confirmed ORR was 46.3% in HER2+, 37.3% in HR+/HER2-, and 34.8% in TNBC among 162 heavily pretreated patients, with PFS 5.8-7.0 months and no interstitial lung disease
Real-world data on chemotherapy choice and adjuvant capecitabine in young BRCA1/2 carriers with HER2-negative early breast cancer — A new study examined chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer

Full details below ↓

📄 What's Being Published

Manuscripts:

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. — Licata L et al., Ann Oncol

Premenopausal women with HR+/HER2-negative early breast cancer represent a clinically distinct population, characterized by more aggressive tumor biology, unique survivorship concerns, and complex treatment decision-making. Adjuvant endocrine therapy, with the addition of CDK4/6 inhibitors in selected higher-risk patients, remains the cornerstone of treatment, yet major uncertainties persist regarding the optimal use of ovarian function suppression, the interpretation of genomic assays to inform chemotherapy decisions, and the selection of candidates for extended endocrine therapy.

Clinical bottom line: In premenopausal HR+/HER2- early breast cancer, endocrine therapy intensity — ovarian function suppression, CDK4/6 inhibition, chemotherapy based on genomic assays — should be individualized by risk and patient priorities rather than escalated reflexively because the patient is young.

Read full article →

🔗 Also discussed on social media →

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial. — Schochter F et al., Breast Cancer Res Treat

In HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells, median PFS and OS with eribulin were 4.6 months and 13.4 months, respectively. CTC-clearance at first follow-up occurred in 34.7% of patients and was associated with significantly improved PFS (p = 0.043) but not OS (p = 0.192); CTC-clearance at end of treatment occurred in 23.1% and similarly yielded better PFS (p = 0.015) but not OS (p = 0.218).

Clinical bottom line: Eribulin remains an effective option in pretreated HER2-negative metastatic breast cancer, and early circulating tumor cell clearance tracks with progression-free survival, supporting CTC dynamics as an early on-treatment response marker rather than a survival surrogate.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

An Annals of Oncology review on premenopausal HR+/HER2- adjuvant therapy becomes the week's most-shared breast paper, with clinicians pointing to its risk-category endocrine figure

The review frames premenopausal HR+/HER2-negative early breast cancer as a clinically distinct population with more aggressive tumor biology and complex treatment decision-making, and clinicians circulated its figure summarizing which endocrine therapy combination fits each risk category — with commentary noting that being young or high-risk should not automatically mean maximal therapy. Optimal selection and duration of endocrine therapy remain key unresolved issues in young women, and interpretation of genomic assays for chemotherapy decisions remains challenging in premenopausal patients. The central debate: whether care for premenopausal women is truly personalized, or still built on evidence largely derived from postmenopausal populations — and in a patient with intermediate-risk disease, what actually tips the decision toward adding ovarian function suppression or a CDK4/6 inhibitor rather than tamoxifen alone.

Discussed by: @stolaney1, @Dr_RShatsky, @Dr_Oncologista, @OncoAlert

→ View representative tweet

Sources cited: Annals of Oncology · ScienceDirect

ABC8 international consensus guidelines for advanced breast cancer: a new endocrine sensitivity/resistance definition, updated subtype algorithms, and first-ever guidance on exercise and artificial intelligence

ABC8 introduces an updated definition of endocrine sensitivity/resistance developed in collaboration with the AURORA Molecular Screening Initiative, alongside new guidelines on clinical trials, exercise, and artificial intelligence, and updated guidance for biomarkers, inflammatory breast cancer, brain imaging, and supportive care. Key therapeutic updates include PATINA and HER2CLIMB-05 maintenance strategies in HER2-positive disease, first-line T-DXd plus pertuzumab as an option where approved, and the role of sacituzumab govitecan and datopotamab deruxtecan in first-line TNBC; the guidelines also give a strong recommendation for structured exercise as part of comprehensive advanced breast cancer care and state that AI may support clinical decision-making but should not replace evidence-based medicine or shared decisions between patients and clinicians. Clinicians framed the question as one of sequencing rather than drug availability — with treatment sequencing now the critical clinical question — and the revised endocrine resistance definition sharpens the debate over whether second-line selection is guided by the new definition or by what each patient has already received.

Discussed by: @to_be_elizabeth, @stolaney1, @JaniceTNBCmets, @Dr_Oncologista, @weoncologists

→ View representative tweet

Sources cited: OncoDaily

FDA approves imlunestrant plus abemaciclib for ESR1-mutated ER+/HER2- advanced breast cancer — the first oral SERD combination in this setting, with immature overall survival

Imlunestrant plus abemaciclib received FDA approval for pretreated patients with ESR1-mutated HR+/HER2- metastatic breast cancer, representing the first approval of an oral SERD combination in this setting; the approval rests on EMBER-3, where in the ESR1-mutant subgroup median PFS was 11.1 vs 5.5 months, HR 0.53, and ORR 35% vs 15%, though the ESR1-mutant analysis was exploratory, the control arm was imlunestrant alone, and overall survival is immature. The restriction to ESR1-mutated tumors reflects that single-agent imlunestrant did not improve PFS versus standard-of-care endocrine therapy in all-comers. Clinicians now count four options in second-line ESR1-mutated metastatic breast cancer — elacestrant, imlunestrant, imlunestrant plus abemaciclib, and vepdegestrant — and placed this approval within a broader run of 10 new FDA indications in breast cancer over 20 weeks from May to September 2026, which included the first PROTAC in any cancer, the first CDK4/6 inhibitor in HER2-positive breast cancer, and the first drug approval triggered by ctDNA prior to radiographic progression.

Discussed by: @OncBrothers, @ErikaHamilton9, @DrBarbiOnc, @Dr_ElvinaA, @jhaveri_komal, @tmprowell, @ErikaHamilton9, @ErikaHamilton9

→ View representative tweet

Sources cited: FDA press release · OncLive

Update: iza-bren's EGFR-HER3 bispecific ADC breast data draw a second week of scrutiny, now focused on therapeutic index and cross-resistance after prior TOP1 inhibitor ADCs

Among 162 heavily pretreated patients, iza-bren produced confirmed ORRs of 46.3% in HER2-positive, 37.3% in HR+/HER2-negative, and 34.8% in TNBC, with PFS of 5.8–7.0 months and duration of response up to 12.3 months in TNBC; no interstitial lung disease occurred, but grade ≥3 treatment-related adverse events occurred in 78%, neutropenia in 56%, and there were 2 treatment-related deaths. Cross-resistance is a material concern: ORR after a prior TOP1 inhibitor ADC was only 10% in HER2-positive disease, prompting clinicians to question where in the sequence this agent actually belongs. The bispecific design — binding both EGFR and HER3, which are often co-expressed, to improve avidity, promote receptor clustering, and capture cells with low EGFR through HER3 — is biologically compelling, but the therapeutic index remains the key clinical question.

Discussed by: @EladSharonMD, @Dr_Oncologista, @OncoAlert, @GlopesMd

→ View representative tweet

Sources cited: Annals of Oncology

Real-world data on chemotherapy choice and adjuvant capecitabine in young BRCA1/2 carriers with HER2-negative early breast cancer

A new study examined chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer; among 882 patients with early TNBC treated with adjuvant capecitabine (6% BRCAm, 94% non-BRCAm), 3-year iDFS was 59% vs 72%, DDFS 59% vs 73%, and OS 67% vs 80% for BRCAm versus non-BRCAm patients, a persistent gap that the authors argue supports broader BRCA testing and the use of adjuvant olaparib in confirmed BRCAm early TNBC. Alongside the outcome data, clinicians noted that not all deleterious BRCA mutations carry equal risk — copy number variants are associated with increased breast cancer risk in BRCA1 carriers — adding granularity to the question of which BRCA1/2 carriers are at greatest residual risk after capecitabine and whether olaparib supplants rather than supplements it.

Discussed by: @stolaney1, @to_be_elizabeth, @DFCI_BreastOnc, @ErikaHamilton9

→ View representative tweet

Sources cited: PubMed · pmc.ncbi.nlm.nih.gov · Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic varian… (Communications Biology, 2022)

A JNCI analysis tries to refine adjuvant CDK4/6 inhibitor selection in early breast cancer by separating anatomic from biologic risk in monarchE and NATALEE criteria

Optimal indications for adjuvant CDK4/6 inhibition in early breast cancer remain debated, particularly regarding the unclear prognostic role of anatomic versus biologic features; a JNCI analysis refined risk stratification according to monarchE and NATALEE criteria to address this gap. Clinicians paired that analysis with a narrative review of the clinical evidence for abemaciclib in HR+/HER2-negative breast cancer, framing the practical question as what to do when anatomic stage and tumor biology point in different directions.

Discussed by: @stolaney1, @DFCI_BreastOnc

→ View representative tweet

Sources cited: PubMed

DESCEND: a steroid-free antiemetic regimen with NEPA plus olanzapine is noninferior to four days of dexamethasone in highly emetogenic chemotherapy

In the phase III DESCEND trial (n=644), complete response rates at 0–120 hours were 72.4% in the standard arm, 72.2% in the dexamethasone-sparing arm, and 70.1% in the dexamethasone-free arm, with both reduced-dexamethasone arms meeting noninferiority confirmed per-protocol; steroid toxicity including insomnia, agitation, and hiccups dropped significantly in both reduced-dexamethasone arms. The relevance to breast oncology is direct: dose-dense chemotherapy — standard doses with the interval shortened from every 3 weeks to every 2 weeks with prophylactic G-CSF — is a key application in breast cancer, making the ability to eliminate multi-day dexamethasone without sacrificing antiemetic efficacy a clinically actionable finding.

Discussed by: @EladSharonMD, @DrRupamOncology

→ View representative tweet

Sources cited: doi.org

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @OncBrothers: Camizestrant is now @FDA ✅ for HR+ metastatic #breastcancer with emersion of mESR1 prior to progression. Here we 🗣️ this trial, findings, & clinical implications w/ @elmayermd

Full 🗣️
⭐️ https://t.co/UShrrDGIlz
⭐️ “Oncology Brothers” podcast

@OncUpdates @OncoAlert #bcsm https://t.co/mWIKlyLT77

🔖 3 ❤️ 19 🔁 12 👁 4,145

📬 Breast Cancer Intelligence Digest — Week 2026-W39

⚡ TL;DR

📄 What's Being Published

🗣️ What People Were Discussing This Week

An Annals of Oncology review on premenopausal HR+/HER2- adjuvant therapy becomes the week's most-shared breast paper, with clinicians pointing to its risk-category endocrine figure

ABC8 international consensus guidelines for advanced breast cancer: a new endocrine sensitivity/resistance definition, updated subtype algorithms, and first-ever guidance on exercise and artificial intelligence

FDA approves imlunestrant plus abemaciclib for ESR1-mutated ER+/HER2- advanced breast cancer — the first oral SERD combination in this setting, with immature overall survival

Update: iza-bren's EGFR-HER3 bispecific ADC breast data draw a second week of scrutiny, now focused on therapeutic index and cross-resistance after prior TOP1 inhibitor ADCs

Real-world data on chemotherapy choice and adjuvant capecitabine in young BRCA1/2 carriers with HER2-negative early breast cancer

A JNCI analysis tries to refine adjuvant CDK4/6 inhibitor selection in early breast cancer by separating anatomic from biologic risk in monarchE and NATALEE criteria

DESCEND: a steroid-free antiemetic regimen with NEPA plus olanzapine is noninferior to four days of dexamethasone in highly emetogenic chemotherapy

🔥 Top Ranked Tweets

🧪 Newly Recruiting Trials